Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track INSM with free AI briefings, catalyst countdowns, and dilution alerts.

INSM · INSMED Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.1B Cash on Hand
54.9mo Cash Runway
7.2% Short Interest
$194.18 Analyst Target (22)
Follow INSM by email Get an email when INSM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about INSM, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoAOptions-implied move
2027-01-28 ARIKAYCE Mycobacterium avium complex lung disease sNDA 86% ±21% by Feb 19

Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What INSM Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Amikacin
FDA approved Sep 2018 · Arikayce Kit
NTM Lung Infection Due to MAC Phase 3 · NCT02628600 Completed
Brensocatib (INS1007)
FDA approved Aug 2025 · Brinsupri
Non-Cystic Fibrosis Bronchiectasis Phase 3 · NCT04594369 Completed
Treprostinil Palmitil Inhalation Powder Pulmonary Arterial Hypertension Phase 3 · NCT07481981 Recruiting
Ethambutol Mycobacterium Infections, Nontuberculous Phase 3 · NCT04677569 Completed
Liposomal amikacin for inhalation (Arikayce™)… Pseudomonas Aeruginosa Infection Phase 3 · NCT01315678 Completed
C-C Motif Chemokine 19 Mycobacterium Infections, Nontuberculous Phase 3 · NCT04677543 Completed
multi-drug regimen NTM Lung Infection Due to MAC Phase 3 · NCT02628600 Completed
Tobramycin inhalation solution using a PARI LC®… Pseudomonas Aeruginosa Infection Phase 3 · NCT01315678 Completed
Treprostinil Palmitil Pulmonary Arterial Hypertension Phase 2/3 · NCT05649748 Active not recruiting
OpSCF Atopic Dermatitis Phase 2 · NCT06101823 Completed
Mometasone Furoate Nasal Spray, 50 mcg Chronic Rhinosinusitis Without Nasal Polyps Phase 2 · NCT06013241 Completed
rhIGF-I/rhIGFBP-3 Myotonic Dystrophy Type 1 Phase 2 · NCT00577577 Completed
INS1033 Healthy Volunteers Phase 1 · NCT07765706 Recruiting
[14C]-brensocatib Healthy Volunteers Phase 1 · NCT05652257 Completed
TPIP F3 Healthy Volunteers Phase 1 · NCT07102316 Completed
TPIP F2 Healthy Volunteers Phase 1 · NCT07102316 Completed

Also used in these trials (approved or third-party drugs, not INSM's own candidates): Azithromycin, Treprostinil, Rifampin, Midazolam Hydrochloride, Clarithromycin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

INSM holds $1.1B in cash and short-term investments (as of Sep 30, 2026) and burns about $62.6M/quarter from operations, an estimated runway of 54.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 40 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INSM files for a raise →

👥 Who Owns INSM

Insiders 0.6% Institutions (1031 holders) 99.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 16,127,583 7.35% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 14,121,445 6.44% 2025-12-31
Vanguard Capital Management Institution (13G, 5%+) 11,514,893 5.25% 2026-03-31
Vanguard Portfolio Management LLC Institution (13F) 10,529,985 4.80% 2026-09-30
Capital International Investors Institution (13F) 9,352,633 4.26% 2026-09-30
Baker Bros. Advisors, LP Institution (13F) 8,796,111 4.01% 2026-09-30
JPMORGAN CHASE & CO Institution (13F) 8,243,537 3.76% 2026-09-30
Orbis Allan Gray Ltd Institution (13F) 6,733,982 3.07% 2026-09-30
Ameriprise Financial, Inc. Institution (13F) 6,251,016 2.85% 2026-09-30
State Street Corporation Institution (13F) 6,162,413 2.81% 2026-09-30
William Lewis
Chair and CEO, Director
Insider 492,982 0.22% 2026-07-23
Melvin Md Sharoky
Director
Insider 267,901 0.12% 2026-08-17

Share count 219,380,309 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-19
filed 2026-10-20
Koppikar Utpal
Award (A) 6,139 – 6,139
2026-10-19
filed 2026-10-20
Hudson Paul
Award (A) 6,139 – 6,139
2026-09-09
filed 2026-09-11
Brennan David R
Sale (S) 25,000 $124.00 39,238
2026-08-17
filed 2026-08-19
SHAROKY MELVIN MD
Sale (S) 5,000 $127.53 0
2026-08-10
filed 2026-08-12
Adsett Roger
Option exercise (M) 80,970 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full INSM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INSM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.